Patient Awareness of CAR-T and Bispecific Antibody Treatments for Multiple Myeloma: Real-World Learnings and Disparities

被引：0
|
作者：
Adu, Yaw [1 ]
Das, Saurav [2 ]
Ailawadhi, Dhaani [3 ]
Fernandez, Andre [2 ]
Parrondo, Ricardo [2 ]
Roy, Vivek [2 ]
Sher, Taimur [2 ]
O'Connell, Sean [4 ]
Rasheed, Ahsan [2 ]
Chanan-Khan, Asher A. [2 ]
Ailawadhi, Sikander [2 ]
机构：
[1] Texas Tech Univ, Hlth Sci Ctr, Sch Med, Lubbock, TX USA
[2] Mayo Clin, Div Hematol Oncol, Jacksonville, FL USA
[3] Bolles Middle Sch, Jacksonville, FL USA
[4] Mayo Clin, Sch Continuous Profess Dev, Jacksonville, FL USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-189642
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Real-world comparison of overall survival between BCMA - bispecific and CAR-T therapies in multiple myeloma
    Song, J.
    Kim, G.
    Memon, R. S.
    Chi, K-Y.
    Chang, Y.
    Mehta, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S597 - S597
  • [2] Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma
    Tacchetti, Paola
    Talarico, Marco
    Barbato, Simona
    Pantani, Lucia
    Mancuso, Katia
    Rizzello, Ilaria
    Zamagni, Elena
    Cavo, Michele
    EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (06) : 379 - 395
  • [3] Real world outcome of patients with multiple myeloma who received bispecific antibodies after CAR-T therapy.
    Bansal, Radhika
    Corraes, Andre De Menezes Silva
    Brunaldi, Larissa
    Sandahl, Tyler B.
    Matthew, Rees J.
    Hayman, Suzanne R.
    Binder, Moritz
    Abdallah, Nadine
    Dingli, David
    Cook, Joselle
    Gertz, Morie A.
    Kapoor, Prashant
    Kourelis, Taxiarchis
    Warsame, Rahma M.
    Kumar, Shaji
    Lin, Yi
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Current status of bispecific antibodies and CAR-T therapies in multiple myeloma
    Szlasa, Wojciech
    Dybko, Jaroslaw
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 134
  • [5] Real-world outcome of myeloma patients qualifying for CAR-T treatment in the pre-CAR-T era
    Brechbuhl, S.
    Bacher, U.
    Jeker, B.
    Pabst, T.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 100 - 101
  • [6] Real-world outcome of myeloma patients qualifying for CAR-T treatment in the pre-CAR-T era
    Brechbuhl, S.
    Bacher, U.
    Jeker, B.
    Pabst, T.
    SWISS MEDICAL WEEKLY, 2020, : 17S - 17S
  • [7] CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY FOR MULTIPLE MYELOMA IN THE US: REAL-WORLD EVALUATION OF PATIENT CHARACTERISTICS AND TREATMENT PATTERNS
    Kish, J.
    Pfeffer, D.
    Cyhaniuk, A.
    Lussier, C.
    Nayak, P.
    Liu, R.
    Prasad, S.
    Sehgal, P.
    VALUE IN HEALTH, 2023, 26 (06) : S58 - S58
  • [8] Disparities in Clinical Trial Enrollment- Focus on CAR-T and Bispecific Antibody Therapies
    Islam, Nadia
    Budvytyte, Laura
    Khera, Nandita
    Hilal, Talal
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2025, 20 (01)
  • [9] BCMAxCD3 Bispecific Antibody Elranatamab Is Effective in Patient Myeloma Relapsed after BCMA CAR-T
    Keller, Alana L.
    Parzych, Sarah E.
    Reiman, Lauren T.
    Walker, Zachary J.
    Forsberg, Peter A.
    Sherbenou, Daniel W.
    BLOOD, 2023, 142
  • [10] Navigating the Economic Burden of Multiple Myeloma: Insights into Cost-effectiveness of CAR-T and Bispecific Antibody Therapies
    Keesari, Praneeth Reddy
    Samuels, Diana
    Vegivinti, Charan Thej Reddy
    Pulakurthi, Yashwitha Sai
    Kudithi, Revathi
    Dhar, Meekoo
    Janakiram, Murali
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2025, 20 (01)
12345